# Phase II Study of Tesetaxel in Metastatic Melanoma

> **NCT01064713** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Advanced Melanoma
- Cancer

## Interventions

- **DRUG:** Tesetaxel

## Key facts

- **NCT ID:** NCT01064713
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2018-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064713, "Phase II Study of Tesetaxel in Metastatic Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01064713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*